Physician

Robert E Reilly, DO

According to 2025 Medicare claims, Robert Reilly, DO (NPI: 1124178819) practices medical oncology in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 19047-1212.

Reilly's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 580 traditional Medicare patients, billed 106,779 HCPCS/CPT codes, and received $1,816,296 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,131 prescription claims across 257 beneficiaries totaling $2,012,512 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2020 DME data shows 17 claims. Open Payments data shows 155 records totaling $3,359. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $481,370 to $2,012,512. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	689	198,497	$2,728,130
2016	707	152,455	$2,530,138
2017	621	188,506	$2,666,500
2018	647	168,218	$2,418,145
2019	668	157,291	$2,407,368
2020	569	142,238	$2,268,939
2021	592	190,925	$2,641,719
2022	557	169,454	$2,551,158
2023	578	116,452	$2,229,133
2024	580	106,779	$1,816,296

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	203	1,006	$481,370
2016	217	1,092	$866,303
2017	234	1,117	$595,306
2018	254	1,106	$857,248
2019	267	1,194	$1,156,100
2020	288	1,392	$2,098,636
2021	293	1,358	$2,359,397
2022	263	1,276	$3,148,755
2023	242	1,111	$2,012,625
2024	257	1,131	$2,012,512

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	73	$21,361
2016	N/R	79	$14,650
2017	N/R	81	$9,638
2018	N/R	73	$8,290
2019	N/R	29	$4,546
2020	N/R	17	$2,817
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	168	368	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	360	675	$71
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	221	301	$14
36415	Insertion of needle into vein for collection of blood sample	357	1,342	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	270	945	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	16	480	$266,412
Xtandi	Enzalutamide	12	360	$168,303
Imbruvica	Ibrutinib	12	340	$156,598
Eliquis	Apixaban	88	3,180	$60,164
Xarelto	Rivaroxaban	33	1,410	$25,016

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	155	$3,359	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert E. Reilly, DO?

Tedicare shows public-source Medicare data for Robert E. Reilly, DO (NPI 1124178819), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert E. Reilly, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert E. Reilly, DO?

Robert E. Reilly, DO is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Robert E. Reilly, DO have Open Payments data?

Robert E. Reilly, DO has 155 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.